SPRINGWORKS THERAPEUTICS, INC.
SWTXUnited States
23 filed reports · 289 financial concepts
Latest figures
Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.
| Figure | Latest fiscal year | Latest quarter |
|---|---|---|
| Revenue | $192MFY2024 · to Dec 31, 2024+3,417% from $5.45M10-K | $49.1MQ1 FY2025 · to Mar 31, 2025+134% from $21M10-Q |
| Net income | -$258MFY2024 · to Dec 31, 2024a year earlier: -$325M10-K | -$83.2MQ1 FY2025 · to Mar 31, 2025a year earlier: -$87.4M10-Q |
| Operating income | -$278MFY2024 · to Dec 31, 2024a year earlier: -$343M10-K | -$80.5MQ1 FY2025 · to Mar 31, 2025a year earlier: -$93.9M10-Q |
Filed reports
23 reports · Sep 2019 to Mar 2025Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 17 | 1,845 | Sep 2019 to Mar 2025 |
| Annual · 10-KSEC EDGAR | 6 | 1,844 | Dec 2019 to Dec 2024 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 9, 2025 | 259 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 20, 2025 | 616 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 12, 2024 | 148 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 7, 2024 | 140 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 2, 2024 | 98 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Feb 27, 2024 | 301 | Open |
| FY2023 Q3 | 10-Q | Sep 30, 2023 | Nov 2, 2023 | 100 | Open |
| FY2023 Q2 | 10-Q | Jun 30, 2023 | Aug 2, 2023 | 95 | Open |
| FY2023 Q1 | 10-Q | Mar 31, 2023 | May 3, 2023 | 108 | Open |
| FY2022 | 10-K | Dec 31, 2022 | Feb 28, 2023 | 304 | Open |
| FY2022 Q3 | 10-Q | Sep 30, 2022 | Nov 3, 2022 | 103 | Open |
| FY2022 Q2 | 10-Q | Jun 30, 2022 | Aug 4, 2022 | 93 | Open |
Financial data
289 concepts · 3,689 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial278 concepts · 3,636 facts · Dec 2017 to Mar 2025
- Cash cash equivalents restricted cash and restricted cash equivalents36 · Dec 2017 to Mar 2025
- Operating income loss36 · Mar 2018 to Mar 2025
- Stockholders equity (US GAAP)35 · Dec 2017 to Mar 2025
- Net income loss34 · Sep 2018 to Mar 2025
- Nonoperating income expense34 · Sep 2018 to Mar 2025
- Research and development expense34 · Sep 2018 to Mar 2025
- Antidilutive securities excluded from computation of earnings per share amount33 · Dec 2018 to Mar 2025
- Increase decrease in accounts payable33 · Dec 2018 to Mar 2025
- Increase decrease in accrued liabilities33 · Dec 2018 to Mar 2025
- Increase decrease in other current assets33 · Dec 2018 to Mar 2025
- Increase decrease in prepaid deferred expense and other assets33 · Dec 2018 to Mar 2025
- Net cash provided by used in financing activities33 · Dec 2018 to Mar 2025
- Net cash provided by used in investing activities33 · Dec 2018 to Mar 2025
- Net cash provided by used in operating activities33 · Dec 2018 to Mar 2025
- Payments to acquire property plant and equipment33 · Dec 2018 to Mar 2025
- Share based compensation33 · Dec 2018 to Mar 2025
- Common stock par or stated value per share32 · Dec 2018 to Mar 2025
- Comprehensive income net of tax32 · Dec 2018 to Mar 2025
- Investment income net32 · Dec 2018 to Mar 2025
- Accounts payable current31 · Dec 2018 to Mar 2025
- Accrued liabilities current31 · Dec 2018 to Mar 2025
- Additional paid in capital31 · Dec 2018 to Mar 2025
- Assets31 · Dec 2018 to Mar 2025
- Assets current31 · Dec 2018 to Mar 2025
Segment10 concepts · 50 facts · Dec 2022 to Mar 2025
- Commercial Expenses5 · Dec 2022 to Mar 2025
- Cost of goods and services sold (US GAAP)5 · Dec 2022 to Mar 2025
- Costs and expenses5 · Dec 2022 to Mar 2025
- General and administrative expense (US GAAP)5 · Dec 2022 to Mar 2025
- Income loss from equity method investments5 · Dec 2022 to Mar 2025
- Investment income net5 · Dec 2022 to Mar 2025
- Medical Expenses5 · Dec 2022 to Mar 2025
- Net income loss5 · Dec 2022 to Mar 2025
- Research and development expense5 · Dec 2022 to Mar 2025
- Revenue5 · Dec 2022 to Mar 2025
Product1 concept · 3 facts · Dec 2023 to Mar 2025
- Revenue3 · Dec 2023 to Mar 2025
Segments
53 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments1 member · 50 facts
- Developing And Commercializing Life Changing Medicines50 · Dec 2022 to Mar 2025
Product or service1 member · 3 facts
- OGSIVEO3 · Dec 2023 to Mar 2025
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Ask about this company in your AI model
Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.
Use FactIQ to get the revenue, net income and operating income of SPRINGWORKS THERAPEUTICS, INC. (SWTX) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 16, 2026) and refreshed every few hours.